ArticlePloS one2019
Plasma sphingomyelins increase in pre-diabetic Korean men with abdominal obesity.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Sex-Dependent Lipidomic Remodeling in Plasma and Feces Following High-Fat Diet Intake in Adult Rats.Nutrients · 2026Article
- Cardiometabolic Factor-Specific Metabolic Signatures in Metabolic Dysfunction-Associated Steatotic Liver Disease: Insights from Non-Targeted Metabolomics.Antioxidants (Basel, Switzerland) · 2026Article
- Hepatic and metabolic effects of SGLT2 inhibitors in type 2 diabetes and MASLD assessed by metabolomic and lipidomic analysis.Scientific reports · 2026Article
- Interventional approaches to combat obesity: Exploring the metabolomic signature of weight loss trials.Metabolism open · 2025Review
- High-fat diet promotes lipotoxicity in the podocytes of uninephrectomized mice: a targeted lipidomics and kidney podocyte-specific analysis.Cell death discovery · 2025Article
- Untargeted lipidomics analysis in women with morbid obesity and type 2 diabetes mellitus: A comprehensive study.PloS one · 2024Article
- Gut microbiota in a mouse model of obesity and peripheral neuropathy associated with plasma and nerve lipidomics and nerve transcriptomics.Microbiome · 2023Article
- Dysregulated Metabolic Pathways in Subjects with Obesity and Metabolic Syndrome.International journal of molecular sciences · 2022Article
- Untargeted Metabolomics Analysis of the Serum Metabolic Signature of Childhood Obesity.Nutrients · 2022Article
- Effect of Korean Red Ginseng on Plasma Ceramide Levels in Postmenopausal Women with Hypercholesterolemia: A Pilot Randomized Controlled Trial.Metabolites · 2021Article
- Metabolic reprogramming of the myeloid lineage by Schistosoma mansoni infection persists independently of antigen exposure.PLoS pathogens · 2021Article
- Sample Preparation Methods for Lipidomics Approaches Used in Studies of Obesity.Molecules (Basel, Switzerland) · 2020Review
- Plasma Lipidomics Reveals Insights into Anti-Obesity Effect ofNutrients · 2020Article
- Sphingolipids Modulate Secretion of Glycosylphosphatidylinositol-Anchored Plasmodesmata Proteins and Callose Deposition.Plant physiology · 2020Article
- Correlation of plasma metabolites with glucose and lipid fluxes in human insulin resistance.Obesity science & practice · 2020Article
- Sphingolipids in Obesity and Correlated Co-Morbidities: The Contribution of Gender, Age and Environment.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abdominal or visceral obesity is a well-known risk factor for metabolic diseases. However, whether abdominal obesity significantly affects plasma lipid profile during the development of type 2 diabetes has not been fully elucidated. We investigated the differences in plasma lipid concentrations in 63 participants categorized into six groups (middle-aged Korean men); Normal, Pre-diabetes (pre-DM), and Diabetes mellitus (DM) with or without abdominal obesity (AO or lean). The lipidomic profiles were determined by using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Sphingomyelin (SM) levels in plasma were significantly higher in the pre-DM with AO than in pre-DM with lean (p = 0.021). SM concentrations correlated positively with waist-to-hip ratio (WHR) (r = 0.256, p = 0.044), cholesteryl ester (CE) (r = 0.483, p < 0.0001), ceramide (r = 0.489, p < 0.0001) and plasmanyl phosphatidylcholine (PC) (r = 0.446, p < 0.0001). The present study found that pre-diabetic patients with AO were characterized by increased plasma concentrations of SM. Plasma SM levels in individuals with AO may be an early prognostic biomarker to better predict the progression toward type 2 diabetes and metabolic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.